Form 4: CytomX Therapeutics CFO Reports Routine Stock Transactions for Tax Purposes

CytomX Therapeutics' Chief Financial Officer, Christopher Ogden, reported the vesting of performance stock units and subsequent sales of common stock to cover tax obligations.

Summary

• Christopher Ogden, Chief Financial Officer of CytomX Therapeutics, Inc. (CTMX), filed a Form 4 detailing recent stock transactions.
• On June 13, 2025, Mr. Ogden acquired 37,500 shares of common stock through the vesting of performance stock units (PSUs) at a price of $0.00 per share. These PSUs were initially granted on February 2, 2023.
• Also on June 13, 2025, 1,641 shares of common stock were sold at a price of $2.9503 per share to satisfy tax or other government withholding obligations related to the vesting of restricted stock units (RSUs).
• On June 16, 2025, an additional 10,614 shares of common stock were sold at a price of $2.6889 per share, also to satisfy tax or other government withholding obligations in connection with the vesting of PSUs.
• Following these transactions, Mr. Ogden's beneficial ownership of common stock stands at 226,271 shares, which includes 149,987 RSUs.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing reports routine, pre-planned insider transactions related to equity compensation and tax obligations, which are common and do not indicate a change in company fundamentals or insider sentiment.

Positives

• The vesting of 37,500 performance stock units (PSUs) indicates that performance targets associated with the grant were met, reflecting positively on the company's operational achievements or stock performance metrics.

Negatives

• The sales of common stock were non-discretionary, solely for the purpose of satisfying tax withholding obligations, and do not reflect a negative outlook on the company by the insider.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing is a routine insider transaction report common across all publicly traded companies, reflecting compensation-related stock activity rather than strategic industry shifts or competitive positioning.

Stakeholder Impact

• Shareholders: The report provides transparency on insider stock ownership and compensation-related transactions, which is standard for publicly traded companies. The sales are for tax purposes and not indicative of a change in investment thesis by the CFO.
• Employees: The vesting of PSUs demonstrates the company's compensation structure and the achievement of performance metrics, which can be a positive signal for employee incentives.

Key Dates

Keywords

CytomX Therapeutics, CTMX, Christopher Ogden, Chief Financial Officer, SEC Form 4, Insider Trading, Stock Transactions, Performance Stock Units, Restricted Stock Units, Equity Compensation, Tax Withholding, Beneficial Ownership